Skip to main content

EDITORIAL article

Front. Neurosci.
Sec. Translational Neuroscience
Volume 18 - 2024 | doi: 10.3389/fnins.2024.1497673
This article is part of the Research Topic Noncoding RNAs in Neurodegenerative Disorders: From Current Insights and Future Directions to Translational Modeling and Therapeutic Approaches View all 5 articles

Editorial: Noncoding RNAs in Neurodegenerative Disorders: From Current Insights and Future Directions to Translational Modeling and Therapeutic Approaches

Provisionally accepted
Yujing Li Yujing Li 1Gonçalo Garcia Gonçalo Garcia 2*Akshay Bhinge Akshay Bhinge 3Satoshi Inoue Satoshi Inoue 4
  • 1 Emory University, Atlanta, United States
  • 2 Universidade de Lisboa, Lisbon, Portugal, Lisbon, Portugal
  • 3 College of Medicine and Health, University of Exeter, Exeter, England, United Kingdom
  • 4 Tokyo Metropolitan Institute of Gerontology, tokyo, Japan, Tokyo, Japan

The final, formatted version of the article will be published soon.

    Neurodegenerative disorders (NDs), such as Alzheimer's disease (AD), Parkinson's disease (PD), and 18 amyotrophic lateral sclerosis (ALS), remain major challenges in medicine, characterized by gradual 19 loss of neuronal structure and function (Mo, 2023;Canoy et al., 2024). Many research studies have 20 shed light on the crucial roles of noncoding RNAs (ncRNAs) in the pathogenesis of these diseases, 21 offering new avenues for diagnosis and therapy (Garcia et al., 2021;Canoy et al., 2024). This research 22 topic focuses on the involvement of various ncRNAs, including piRNAs, microRNAs (miRNAs), long 23 noncoding RNAs (lncRNAs), circular RNAs (circRNAs) and competing endogenous RNAs (ceRNAs), 24 in the NDs, as well as exploring future directions for translating these findings into clinical therapies. 25The studies presented in this research topic provide valuable insights into the molecular mechanisms 26 governed by the ncRNAs and their potential to serve as both biomarkers and therapeutic targets. 27 In

    Keywords: non-coding RNA, neurodegenerative disorders (NDs), Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic lateral sclerosis (ALS), miRNA, piRNA, lncRNA

    Received: 17 Sep 2024; Accepted: 14 Oct 2024.

    Copyright: © 2024 Li, Garcia, Bhinge and Inoue. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Gonçalo Garcia, Universidade de Lisboa, Lisbon, Portugal, Lisbon, Portugal

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.